Zycortal for Dogs - Treating Addison's Disease with Zycortal
Zycortal is the UK’s only veterinary registered treatment for Addison’s disease. Zycortal contains the active ingredient desoxycortone pivalate (DOCP).
Zycortal is a veterinary medicine used to treat dogs with Addison's disease. Addison's disease is a condition, known as hypoadrenocorticism, where the adrenal glands (located above the kidneys) do not produce enough of two steroid hormones, called cortisol and aldosterone. Addison's disease (hypoadrenocorticism) is a condition caused by the under production of certain hormones by the adrenal gland. In dogs it causes lethargy, weakness and vomiting. Zycortal is the UK's only veterinary registered treatment for this disease which contains a unique compound, desoxycortone pivalate (DOCP), that helps maintain normal electrolyte balance. This helps reverse the lethargy, vomiting and weakness so often seen with Addison’s diseas...
Zycortal for Dogs - Treating Addison's Disease with Zycortal
Zycortal is the UK’s only veterinary registered treatment for Addison’s disease. Zycortal contains the active ingredient desoxycortone pivalate (DOCP).
Zycortal is a veterinary medicine used to treat dogs with Addison's disease. Addison's disease is a condition, known as hypoadrenocorticism, where the adrenal glands (located above the kidneys) do not produce enough of two steroid hormones, called cortisol and aldosterone. Addison's disease (hypoadrenocorticism) is a condition caused by the under production of certain hormones by the adrenal gland. In dogs it causes lethargy, weakness and vomiting. Zycortal is the UK's only veterinary registered treatment for this disease which contains a unique compound, desoxycortone pivalate (DOCP), that helps maintain normal electrolyte balance. This helps reverse the lethargy, vomiting and weakness so often seen with Addison’s disease.
VETERINARY PRESCRIPTION REQUIRED
Zycortal is a mineralocorticoid replacement therapy (MRT) for dogs with Addison’s disease. Zycortal can be used alone or in combination with glucocorticoids to meet the disease-modifying goals of therapy. DOCP is a long-acting analog of desoxycorticosterone, an endogenous steroid hormone and precursor to aldosterone. When administered parenterally, it produces the same physiologic effects as endogenous aldosterone.